Clinical Trial Update: Erlotinib as First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) for Patients Unfit for Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating erlotinib as first-line therapy for advanced non-small cell lung cancer in patients unfit for chemotherapy has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tarceva (erlotinib)

Snippet

Sponsor: Rigshospitalet, Denmark | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED